TAF9

Across TCGA pan-cancer cohorts, TAF9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAF9 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TAF9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAF9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, ESCA, and KIRP are the cancer types where TAF9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.112	0.743	<.001	24	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
KIRP	OS	Median	All	0.608	0.903	.029	6	view →
UCEC	DFS	Median	All	1.000	0.625	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TAF9–LUSC (OS)

Open the LUSC breakdown →